Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
REGULATORY
Alexion’s Bleeding Antidote to Be Approved as Early as This Month
Japan’s health ministry plans to approve Alexion Pharmaceuticals’ andexanet alfa, an antidote for factor Xa inhibitors, now that it has cleared issues around its data integrity, an official said on March 23. The approval is expected as early as this…
To read the full story
Related Article
- Japan Approves Kerendia, Vabysmo, Ondexxya, Takhzyro and More
March 29, 2022
- Japan Approves Array of Fertility Treatments ahead of Coverage Rollout
March 16, 2022
- Panel Confirms Backing for Alexion’s Bleeding Antidote after Data Integrity Issues
March 10, 2022
- Alexion’s Bleeding Antidote Up for PAFSC Discussion Again after Data Integrity Issues
March 3, 2022
- Fertility Treatment Indications for 9 Meds to Be Reported to PAFSC Panel on March 9
February 25, 2022
- Data Integrity Risk Detected for Alexion’s Approval-Pending Bleeding Antidote, Report to Panel Put on Hold
September 24, 2021
- MHLW Panel Shelves Decision on Entresto’s Hypertension Use, Clears Otsuka’s Eczema Med and More
August 31, 2021
REGULATORY
- Scrap Off-Year Price Revisions, Smaller Japan Firms Face Uphill Battle: DPP Exec
November 28, 2024
- DPP Confirms Plan to Urge 4 Ministers to Scrap Off-Year Price Revisions
November 28, 2024
- Panel OKs 1-Year Extension of HPV Catch-Up Vaccinations, with Strings Attached
November 28, 2024
- Sakigake Tag Granted for Iclepertin, Brogidirsen
November 28, 2024
- MHLW Seeks Comments on Rx-to-OTC Switch of Tadalafil, 2 Other APIs
November 27, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…